Compare SIBN & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIBN | FULC |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 622.3M | 535.5M |
| IPO Year | 2018 | 2019 |
| Metric | SIBN | FULC |
|---|---|---|
| Price | $13.30 | $7.12 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 8 |
| Target Price | ★ $23.88 | $16.38 |
| AVG Volume (30 Days) | 614.3K | ★ 721.5K |
| Earning Date | 05-11-2026 | 04-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 41.33 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $67,301,000.00 | N/A |
| Revenue This Year | $16.95 | N/A |
| Revenue Next Year | $14.93 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 21.53 | N/A |
| 52 Week Low | $11.80 | $4.78 |
| 52 Week High | $21.89 | $15.74 |
| Indicator | SIBN | FULC |
|---|---|---|
| Relative Strength Index (RSI) | 50.04 | 40.86 |
| Support Level | $12.15 | $6.39 |
| Resistance Level | $13.87 | $7.09 |
| Average True Range (ATR) | 0.72 | 0.51 |
| MACD | -0.05 | -0.06 |
| Stochastic Oscillator | 51.80 | 12.42 |
SI-BONE Inc is a medical device company that develops and commercializes a proprietary minimally invasive surgical implant system in the United States and internationally. Its products include a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products such as iFuse-3D, iFuse-TORQ, and iFuse Bedrock Granite, which have applications across sacroiliac joint dysfunction and fusion, adult spinal deformity and degeneration, and pelvic trauma.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.